Similar articles

• Role of ceramides in nonalcoholic fatty liver disease.

  Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. Pagadala M, et al. Trends Endocrinol Metab. 2012 Aug;23(8):365-71. doi: 10.1016/j.tem.2012.04.005. Epub 2012 May 17. Trends Endocrinol Metab. 2012. PMID: 22609053 Free PMC article.
• Metabolic syndrome and NASH.

  Marchesini G, Marzocchi R. Marchesini G, et al. Clin Liver Dis. 2007 Feb;11(1):105-17, ix. doi: 10.1016/j.cld.2007.02.013. Clin Liver Dis. 2007. PMID: 17544974 Review.
• [Candidate drugs for non-alcoholic steatohepatitis (NASH)].

  Terai S, Matsumoto T, Sakaida I. Terai S, et al. Nihon Yakurigaku Zasshi. 2007 Apr;129(4):271-5. doi: 10.1254/fpj.129.271. Nihon Yakurigaku Zasshi. 2007. PMID: 17435339 Review. Japanese. No abstract available.
• [Adipokine interrelationship with the liver].

  Takei Y, Sato N. Takei Y, et al. Nihon Rinsho. 2006 Jun;64(6):1083-7. Nihon Rinsho. 2006. PMID: 16768113 Review. Japanese.
• Pathogenesis of non-alcoholic steatohepatitis: human data.

  Edmison J, McCullough AJ. Edmison J, et al. Clin Liver Dis. 2007 Feb;11(1):75-104, ix. doi: 10.1016/j.cld.2007.02.011. Clin Liver Dis. 2007. PMID: 17544973 Review.